CorMedix Inc. (CRMD) shareholders are optimistic as analysts upgraded revenue and earnings forecasts for next year. Predicted revenues for 2025 are $111m, and EPS is estimated at $0.45. Despite the positive outlook, the stock's price target remains at $14.